000 04119nam a22003615i 4500
001 234676
003 ES-VaUE
005 20221220020618.0
007 cr nn 008mamaa
008 100301s2001 xxu| s |||| 0|eng d
020 _a9781592591442
024 7 _a10.1385/1592591442
_2doi
040 _aES-MaUEC
_bspa
_cES-MaUEC
245 1 0 _aRenal Cancer
_bMethods and Protocols
_cedited by Jack H. Mydlo.
250 _a1st edition 2001
264 1 _aTotowa, NJ
_bHumana Press
_c2001
300 _a1 recurso en línea (XII, 403 páginas)
_b55 ilustraciones
336 _atexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
490 0 _aMethods in Molecular Medicine
_x1940-6037
_v53
505 0 _aRenal Cell Carcinoma -- Pathology of Kidney Tumors -- In Vitro Experimental Techniques -- Telomerase Assay in Renal Cancer -- Comparative Genomic Hybridization -- Analyzing the FHIT Gene by RT-PCR, Western Blotting, and Immunohistochemistry -- Detection of Apoptosis in Renal Cell Carcinoma -- Fluorescence In Situ Hybridization (FISH) to Metaphase and Interphase Chromosomes -- Polymerase Chain Reaction Detection of DNA Sequence Deletions -- Matrix Metalloproteinases and Their Inhibitors -- Purification of Growth Factor mRNA in Renal Tissues:bFGF-2, FGF-2, TGF?, and EGFR -- Laser-Capture Microdissection -- Expression of c-met and WT-1 -- Molecular Analysis of the von Hippel-Lindau Disease Gene -- Experimental Models and Methods in Antibody Targeting of Renal Cell Carcinoma -- In Vivo Experimental Techniques -- Orthotopic Model of Renal Cell Carcinoma -- Murine Animal Model -- Angiogenesis Assays -- Antiangiogenic Approaches to Renal Cell Carcinoma -- Clinical Trials and Experiments -- Interferon Alpha, GM-CSF-Activated T Cells, and IL-6 in Renal Cell Carcinoma -- Immunotherapeutic Approach to Cancer with Cutaneous DNA Vaccination -- Monoclonal Antibodies -- Treatment Strategies in Metastatic Renal Cell Carcinoma -- 23 Assessment of T-Cell Immune Dysfunction in Patients with Renal Cell Carcinoma -- Transforming Growth Factor-?1 as a Novel Marker of Response to Therapy for Renal Cell Carcinoma -- Static and Flow Cytometry.
520 _aBecause renal cancer can be managed successfully only when localized, there is a great need to develop new treatments for patients with advanced or metastatic disease. In Renal Cancer: Methods and Protocols, Jack H. Mydlo, MD, and a panel of leading clinicians and researchers review every aspect of the latest surgical, medical, and immunological therapies that can be used in the diagnosis and treatment of renal cancer. These broadly experienced investigators also present a practical account of their best basic research methods, including the use of reverse transcriptase PCR combined with genomic hybridization, cadherin, and metalloproteinase expression to reveal important factors in the detection, staging, aggressiveness, and treatment of this disease. Gene therapy, the generation of monoclonal antibodies, and the use of interferon alpha, GM-CSF, and IL-6 are also discussed. In vivo assays are provided for analyzing angiogenesis, anti-angiogenesis, and general renal tumor biology as a prelude to human clinical trials. Comprehensive and pioneering, Renal Cancer: Methods and Protocols offers urologists, medical oncologists, laboratory investigators, and pathologists a practical collection of the major cutting-edge techniques and therapies for renal cancer today, together with a view of the highly promising future of gene therapy.
700 1 _aMydlo, Jack H
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
776 0 8 _iPrinted edition:
_z9781617372087
776 0 8 _iPrinted edition:
_z9780896038288
776 0 8 _iPrinted edition:
_z9781489942098
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1385/1592591442
_z(usuarios Universidad Europea de Valencia)
942 _2lcc
_cLE
988 _aSpringer_Protocols_2001
999 _c234676
_d234676